Lily Lin

Summary

Affiliation: Cerus Corporation
Country: USA

Publications

  1. ncbi Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment
    Lily Lin
    Cerus Corporation, Concord, California 94520, USA
    Transfusion 45:1610-20. 2005
  2. ncbi Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria
    Lily Lin
    Cerus Corporation, Concord, California 94520, USA
    Transfusion 44:1496-504. 2004
  3. ncbi Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light
    Lily Lin
    Cerus Corporation, Concord, California, USA
    Transfusion 45:580-90. 2005
  4. ncbi Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function
    Yasmin Singh
    Cerus Corp, Concord, California 94520, USA
    Transfusion 46:1168-77. 2006
  5. doi The extent of amotosalen photodegradation during photochemical treatment of platelet components correlates with the level of pathogen inactivation
    Weiqun Liu
    Cerus Corp, Concord, California 94520, USA
    Transfusion 51:52-61. 2011
  6. doi Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1-month intravenous toxicity study in neonatal rats
    Vic Ciaravino
    Cerus Corporation, Stanwell Drive, Concord, California 94520, USA
    Transfusion 49:985-94. 2009
  7. doi Photochemical inactivation with amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components
    Philippe Grellier
    Biologie Fonctionnelle des Protozoaires, Museum national d histoire naturelle, Paris, France
    Transfusion 48:1676-84. 2008
  8. ncbi Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen
    Jean Claude Osselaer
    Blood Transfusion Center and Laboratory of Hematology, Cliniques Universitaires de Mont Godinne, Universite Catholique de Louvain, Yvoir, Belgium
    Transfusion 48:108-17. 2008
  9. ncbi The efficacy of photochemical treatment with amotosalen HCl and ultraviolet A (INTERCEPT) for inactivation of Trypanosoma cruzi in pooled buffy-coat platelets
    Emma Castro
    From the Spanish Red Cross Transfusion Center, and the National Research Council, Autonomous University of Madrid, Madrid, Spain
    Transfusion 47:434-41. 2007
  10. ncbi Quantification of viral inactivation by photochemical treatment with amotosalen and UV A light, using a novel polymerase chain reaction inhibition method with preamplification
    Jean Pierre Allain
    University of Cambridge, Cambridge, United Kingdom
    J Infect Dis 194:1737-44. 2006

Collaborators

  • L Corash
  • Yasmin Singh
  • Sheila Lukehart
  • Robert S Lane
  • Celso Bianco
  • Richard J Benjamin
  • L T Goodnough
  • Lynette Sawyer
  • Jean Claude Osselaer
  • Jeffrey McCullough
  • Ritchard G Cable
  • J P Allain
  • Tor Hervig
  • M E Brecher
  • M A Blajchman
  • Sherrill Slichter
  • Hans Gulliksson
  • Per Ljungman
  • Maureen G Conlan
  • Jean Pierre Cazenave
  • Karin Janetzko
  • Jocelyne Flament
  • Veronique Mayaudon
  • Peyton Metzel
  • Weiqun Liu
  • Vic Ciaravino
  • Peter Schlenke
  • Philippe Grellier
  • Walter Nussbaumer
  • Emma Castro
  • Daniel Kientz
  • Anne C Simonsen
  • Alvaro Pineda
  • Jin Sying Lin
  • Margaret Rheinschmidt
  • Iris Bruchmüller
  • Bruno Lioure
  • Harald Kluter
  • Stephane Marblie
  • Edward Snyder
  • Kathryn Davis
  • Dick van Rhenen
  • George D Cimino
  • Theresa Sullivan
  • Jessica Hanover
  • Kent Dupuis
  • Marie Louise Wiesel
  • Jorge Benach
  • Matthias Steiert
  • Herve Isola
  • Sebastien Charneau
  • Horacio Gil
  • Linda Pinkoski
  • Ryan Alfonso
  • Gloria Monsalve
  • Mehdi Labaied
  • José Luis Bueno
  • Diether Schönitzer
  • Doris Allerstorfer
  • Javier Carrión
  • Doris Allersdorfer
  • Christoph Grabmer
  • Manuel Fresno
  • Nuria Girones
  • Cornelia Lass-Flörl
  • Niels Borregaard
  • Seth Porter
  • Michele Jacquet
  • Edwin Burgstaler
  • Ronald G Strauss
  • Pär I Johansson
  • Klaus Junge
  • Henning Sørensen
  • Peter Bugert
  • Harold Klüter
  • Martine Michel
  • Jan Hastka
  • Photis Beris
  • D H Buchholz
  • Thomas Raife
  • Laurene Baril
  • George Cimino
  • Derwood Pamphilon
  • Georgine de Greef
  • Don Buchholz
  • Maureen Conlan
  • Mies Kappers-Klunne
  • Hans Vermeij
  • Michel Laforet

Detail Information

Publications21

  1. ncbi Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment
    Lily Lin
    Cerus Corporation, Concord, California 94520, USA
    Transfusion 45:1610-20. 2005
    ..The INTERCEPT Blood System (Baxter Healthcare Corp., and Cerus Corp.) is a photochemical treatment (PCT) process that uses amotosalen (S-59) and ultraviolet A (UVA) illumination to inactivate a broad spectrum of pathogens...
  2. ncbi Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria
    Lily Lin
    Cerus Corporation, Concord, California 94520, USA
    Transfusion 44:1496-504. 2004
    ..A photochemical treatment (PCT) process with amotosalen HCl and long-wavelength ultraviolet light (UVA), which cross-links nucleic acids, was developed to inactivate bacteria and other pathogens in PLT concentrates...
  3. ncbi Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light
    Lily Lin
    Cerus Corporation, Concord, California, USA
    Transfusion 45:580-90. 2005
    ..A photochemical treatment (PCT) process with amotosalen-HCl and long-wavelength ultraviolet light (UVA), which cross-links nucleic acids, was developed to inactivate viruses and other pathogens in PLT concentrates...
  4. ncbi Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function
    Yasmin Singh
    Cerus Corp, Concord, California 94520, USA
    Transfusion 46:1168-77. 2006
    ..These studies evaluated the efficacy of PCT to inactivate pathogens in plasma and the effect of PCT on plasma function...
  5. doi The extent of amotosalen photodegradation during photochemical treatment of platelet components correlates with the level of pathogen inactivation
    Weiqun Liu
    Cerus Corp, Concord, California 94520, USA
    Transfusion 51:52-61. 2011
    ..The levels of amotosalen and photoproducts can be accurately quantified...
  6. doi Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1-month intravenous toxicity study in neonatal rats
    Vic Ciaravino
    Cerus Corporation, Stanwell Drive, Concord, California 94520, USA
    Transfusion 49:985-94. 2009
    ..Because clinical studies in neonates are technically difficult and ethically challenging, preclinical toxicologic studies were conducted in neonatal rats to evaluate the safety of PCT blood components for neonates...
  7. doi Photochemical inactivation with amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components
    Philippe Grellier
    Biologie Fonctionnelle des Protozoaires, Museum national d histoire naturelle, Paris, France
    Transfusion 48:1676-84. 2008
    ....
  8. ncbi Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen
    Jean Claude Osselaer
    Blood Transfusion Center and Laboratory of Hematology, Cliniques Universitaires de Mont Godinne, Universite Catholique de Louvain, Yvoir, Belgium
    Transfusion 48:108-17. 2008
    ..Two methods for treatment of single plasma units are available: amotosalen plus ultraviolet A light and methylene blue plus visible light. This study compared the quality and stability of plasma treated with these two methods...
  9. ncbi The efficacy of photochemical treatment with amotosalen HCl and ultraviolet A (INTERCEPT) for inactivation of Trypanosoma cruzi in pooled buffy-coat platelets
    Emma Castro
    From the Spanish Red Cross Transfusion Center, and the National Research Council, Autonomous University of Madrid, Madrid, Spain
    Transfusion 47:434-41. 2007
    ..This study evaluated the efficacy of photochemical treatment (PCT) with amotosalen and ultraviolet A (UVA) light to inactivate Trypanosoma cruzi in contaminated platelet (PLT) components...
  10. ncbi Quantification of viral inactivation by photochemical treatment with amotosalen and UV A light, using a novel polymerase chain reaction inhibition method with preamplification
    Jean Pierre Allain
    University of Cambridge, Cambridge, United Kingdom
    J Infect Dis 194:1737-44. 2006
    ..We evaluated a novel, efficient polymerase chain reaction (PCR) inhibition assay and examined correlations with reductions in infectivity...
  11. doi Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers
    Peter Schlenke
    University of Lubeck, Institute of Immunology and Transfusion Medicine, Lubeck, Germany
    Transfusion 48:697-705. 2008
    ..Process validation studies were performed in three European blood centers under routine operating conditions...
  12. ncbi Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial
    Alvaro Pineda
    Mayo Clinic, Rochester, Minnesota, USA
    Transfusion 46:562-71. 2006
    ..The system comprises PLT additive solution (PAS III), amotosalen HCl, a compound adsorption device (CAD), a microprocessor-controlled ultraviolet A light source, and a commercially assembled system of interconnected plastic containers...
  13. ncbi Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial
    Jeffrey McCullough
    University of Minnesota, MMC 609, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Blood 104:1534-41. 2004
    ..02). The incidence of grade 2 bleeding was equivalent for PCT and conventional platelets, although posttransfusion platelet count increments and days to next transfusion were decreased for PCT compared with conventional platelets...
  14. ncbi Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light
    Edward Snyder
    Yale University Medical School, Yale New Haven Hospital, New Haven, Connecticut, USA
    Transfusion 44:1732-40. 2004
    ..A photochemical treatment (PCT) method to inactivate pathogens in platelet concentrates has been developed. The system uses a psoralen, amotosalen HCl, coupled with ultraviolet A (UVA) illumination...
  15. ncbi Protecting the blood supply from emerging pathogens: the role of pathogen inactivation
    Jean Pierre Allain
    Department of Hematology, University of Cambridge, Cambridge Blood Centre, UK
    Transfus Med Rev 19:110-26. 2005
    ..However, widespread use of a pathogen inactivation technology can only be realized when proven safe and efficacious and not cost-prohibitive...
  16. ncbi Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set
    Karin Janetzko
    Institute of Transfusion Medicine and Immunology, Red Cross Blood Service of Baden Württemberg Hessen, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Friedrich Ebert Strasse 107, 68167 Mannheim, Germany
    Transfusion 45:1443-52. 2005
    ..compared with conventional apheresis PLTs (reference)...
  17. ncbi Polymerase chain reaction inhibition assay documenting the amotosalen-based photochemical pathogen inactivation process of platelet concentrates
    Iris Bruchmüller
    Institute of Transfusion Medicine and Immunology, Red Cross Blood Service of Baden Württemberg Hessen, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Friedrich Ebert Strasse 107, 68167 Mannheim, Germany
    Transfusion 45:1464-72. 2005
    ....
  18. ncbi Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study
    Anne C Simonsen
    Copenhagen University Hospital, Copenhagen, Denmark
    Transfusion 46:424-33. 2006
    ..Photochemical treatment (PCT) of platelets (PLTs) with amotosalen and ultraviolet A light to inactivate bacteria may facilitate extension of storage from 5 to 7 days...
  19. ncbi Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial
    Dick van Rhenen
    Sanquin Blood Bank South West Region, Rotterdam, The Netherlands
    Blood 101:2426-33. 2003
    ..Platelet components prepared with PCT offer the potential to further improve the safety of platelet transfusion using technology compatible with current methods to prepare buffy coat platelet components...
  20. ncbi Evaluation of bacterial inactivation in prestorage pooled, leukoreduced, whole blood-derived platelet concentrates suspended in plasma prepared with photochemical treatment
    Mark E Brecher
    Department of Pathology and Laboratory Medicine, University of North Carolina, 101 Manning Drive, Chapel Hill, NC 27514, USA
    Transfusion 47:1896-901. 2007
    ..Because PLT additive solutions (ASs) are not used in the United States, this study evaluated the ability of the PCT process to inactivate low levels of bacteria in pooled whole blood-derived PLTs (RDP) suspended in 100 percent plasma...
  21. ncbi Prevention of transfusion of platelet components contaminated with low levels of bacteria: a comparison of bacteria culture and pathogen inactivation methods
    Walter Nussbaumer
    Department of Transfusion Medicine and the Institute for Hygiene and Social Medicine, University of Innsbruck, University Hospital Innsbruck, Innsbruck, Austria
    Transfusion 47:1125-33. 2007
    ..This study compared the efficacy of bacterial detection with inactivation for reducing the risk associated with transfusion of platelet (PLT) components contaminated with low levels of bacteria...